<SEC-DOCUMENT>0001178913-22-000899.txt : 20220303
<SEC-HEADER>0001178913-22-000899.hdr.sgml : 20220303
<ACCEPTANCE-DATETIME>20220303071004
ACCESSION NUMBER:		0001178913-22-000899
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220303
FILED AS OF DATE:		20220303
DATE AS OF CHANGE:		20220303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BioLineRx Ltd.
		CENTRAL INDEX KEY:			0001498403
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35223
		FILM NUMBER:		22706725

	BUSINESS ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871
		BUSINESS PHONE:		972-2-548-9100

	MAIL ADDRESS:	
		STREET 1:		2 HAMA-AYAN STREET
		STREET 2:		MODI-IN TECHNOLOGY PARK
		CITY:			MODI-IN
		STATE:			L3
		ZIP:			7177871

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioLineRX, Ltd.
		DATE OF NAME CHANGE:	20100805
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2227405.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-size: 14pt;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FORM 6-K</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE SECURITIES EXCHANGE ACT OF 1934</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">For the month of March 2022</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Commission file number: 001-35223</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">BioLineRx Ltd.</div>
      <div style="text-align: center; line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">2 HaMa&#8217;ayan Street<br>
        Modi&#8217;in 7177871, Israel</div>
      <div style="text-align: center; line-height: 1.25;">&#160;(Address of Principal Executive Offices)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25;">_______________________</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: &#160; &#160; &#160; &#160;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form 20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160; &#160; &#160; &#160; &#160; Form 40-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25;">On March 3, 2022 the registrant issued the press release which is filed as <a href="exhibit_1.htm"><u>Exhibit 1</u></a>
        to this Report on Form 6-K.</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">The first two paragraphs of the press release attached to this Form 6-K are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
        <div style="page-break-after: always;" id="DSPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"> <br>
      </div>
      <div style="line-height: 1.25;"> </div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z000e5e28b0af4c038f16acdbfaaea72f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.97%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 27.05%; vertical-align: top;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">BioLineRx Ltd.</div>
            <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          </td>
          <td style="width: 22.98%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.97%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.09%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 23.96%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="line-height: 1.25;">/s/ Philip A. Serlin</div>
          </td>
          <td style="width: 22.98%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.97%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.09%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.96%; vertical-align: top;">
            <div style="line-height: 1.25;">Philip A. Serlin</div>
          </td>
          <td style="width: 22.98%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.97%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.09%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23.96%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer</div>
          </td>
          <td style="width: 22.98%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25;">Dated: March 3, 2022</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using EDGARfilings PROfile 8.1.0.0
         Copyright 1995 - 2022 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div id="DSPFPageHeader">
      <div style="line-height: 1.25; text-align: right;">
        <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u><font style="font-weight: bold;">Exhibit 1</font></u><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><img width="285" height="38" src="image00001.jpg"></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-weight: bold;">For Immediate Release</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">BioLineRx Announces Additional Positive Results from </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">Pharmacoeconomic Study Comparing Motixafortide + G-CSF </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">to Plerixafor + G-CSF in Stem Cell Mobilization</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;">- Results demonstrate highly significant cost benefits of using Motixafortide in </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;">combination with G-CSF, versus plerixafor with G-CSF, for stem cell mobilization in all </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;">multiple myeloma patients undergoing autologous stem cell transplantation -</div>
    <div style="line-height: 1.25; font-size: 12pt;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;">- Results reinforce and enhance the economic benefit seen in earlier evaluation of </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: italic; font-weight: bold;">Motixafortide in combination with G-CSF, versus G-CSF alone, reported in Oct 2021 -</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Tel Aviv, Israel, March 3, 2022 &#8211; BioLineRx Ltd. (NASDAQ/TASE: BLRX), a late clinical-stage biopharmaceutical company focused on
      oncology, today announced additional positive results from a follow-on pharmacoeconomic study that was performed based on data from the Company&#8217;s <u>successful Phase 3
          GENESIS trial</u>. This new study indirectly evaluated the cost-effectiveness of using the investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent in combination with granulocyte colony stimulating factor
      (G-CSF), against plerixafor in combination with G-CSF, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The results from the follow-on study, which was performed by the&#160;Global Health Economics and Outcomes
      Research&#160;(HEOR) team of IQVIA, reinforce and enhance the economic benefits previously seen in the main study evaluating Motixafortide in combination with G-CSF, versus G-CSF alone, as part of the GENESIS study, on which the Company reported in <u>October 2021</u>.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The additional study results show that Motixafortide in combination with G-CSF, versus plerixafor in combination with G-CSF,
      demonstrates a statistically significant decrease in health resource utilization (HRU) during the ASCT process. Based on the significantly higher number of mobilized cells and the lower number of apheresis sessions, lifetime estimates show
      quality-adjusted-life-year (QALY) benefits and net cost savings of ~$30,000 (not including the cost of Motixafortide), versus plerixafor plus G-CSF. The study findings strengthen the assessment that the use of Motixafortide in combination with G-CSF,
      as the potential new standard of care in mobilization for ASCT, would be a cost-effective option in the US, based on accepted willingness-to-pay (WTP) values for healthcare payers.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;The results of this pharmacoeconomic study have now demonstrated significant net cost savings of using Motixafortide plus G-CSF, versus
      both plerixafor plus G-CSF and versus G-CSF alone,&#8221; stated Philip Serlin, Chief Executive Officer of BioLineRx. &#8220;These savings relative to available stem cell mobilization options, along with the vastly improved clinical outcomes demonstrated by our
      GENESIS Phase 3 study showing that nearly 90% of patients collected an optimal number of cells for transplantation following a single administration of Motixafortide and in only one apheresis session, further strengthen the commercial case for
      Motixafortide in combination with G-CSF in stem cell mobilization.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;This stronger performance and efficiency are particularly crucial when considering the trend toward more aggressive induction treatment
      protocols that leave patients needing more effective mobilization options. Accordingly, we believe our product has the potential to become the new standard of care for all multiple myeloma patients undergoing autologous stem cell transplantation, and
      potentially for other indications as well, addressing a market with estimated potential revenues of more than $360 million in the US alone. Our team is working diligently to bring this product to patients, and we now expect to file an NDA submission
      in mid-2022. If approved, Motixafortide would represent the first significant advancement in stem cell mobilization since the approval of plerixafor in 2008, and we intend to maximize the value of this opportunity for shareholders,&#8221; Mr. Serlin
      concluded.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About the Follow-on Pharmacoeconomic Study</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The follow-on study was performed by the Global Health Economics and Outcomes Research (HEOR) team of IQVIA, as a supplemental analysis
      to the original pharmacoeconomic study announced in October 2021 comparing motixafortide + G-CSF to G-CSF alone. For this follow-on study, an adjusted indirect comparison was undertaken, using data from the relevant phase 3 trials, to compare
      motixafortide + G-CSF with plerixafor + G-CSF, in stem cell mobilization in patients with multiple myeloma. This included finding and extracting efficacy data for both Motixafortide (from GENESIS patient-level data) and plerixafor (aggregate data
      from literature), estimating plerixafor efficacy as if it had been one arm of the GENESIS trial (Bucher method), and implementing the results in the cost-effectiveness model.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About the GENESIS Phase 3 Trial</div>
    <div style="text-align: justify; line-height: 1.25;">The GENESIS Phase 3 trial (NCT03246529) was initiated in December 2017. GENESIS was a randomized, placebo-controlled, multicenter study,
      evaluating the safety, tolerability and efficacy of Motixafortide and G-CSF, compared to placebo and G-CSF, for the mobilization of hematopoietic stem cells for autologous transplantation in multiple myeloma patients. The primary objective of the
      study was to demonstrate that only one dose of Motixafortide on top of G-CSF is superior to G-CSF alone in the ability to mobilize &#8805; 6 million CD34+ cells in up to two apheresis sessions. Additional objectives included time to engraftment of
      neutrophils and platelets and durability of engraftment, as well as other efficacy and safety parameters. The study successfully met all primary and secondary endpoints with an exceptionally high level of statistical significance (p&lt;0.0001),
      including approximately 90% of patients who mobilized the target number of cells for transplantation with only one administration of Motixafortide and in only one apheresis session.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Stem Cell Mobilization for Autologous Stem Cell Transplantation</div>
    <div style="text-align: justify; line-height: 1.25;">Autologous stem cell transplantation (ASCT) is part of the standard treatment paradigm for a number of blood cancers, including multiple
      myeloma, non-Hodgkin&#8217;s lymphoma and other lymphomas. In eligible patients, ASCT is performed after initial (induction) therapy, and, in most cases, requires consecutive-day clinic visits for the mobilization and apheresis (harvesting) phases, and
      full hospitalization for the conditioning chemotherapy and transplantation phases until engraftment. The associated burden is therefore significant &#8211; patients experience clinically relevant deteriorations in their quality of life during ASCT, and
      healthcare resource use throughout the ASCT phases is particularly intense. Therefore, new interventions impacting the ASCT process have the potential for relieving some of the clinical burden for transplanted patients, the logistical burden for the
      apheresis units, and the financial burden for healthcare providers and payers.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Described simply, ASCT consists of: (1) mobilizing the patient&#8217;s own stem cells from his/ her bone marrow to the peripheral blood for
      removing (harvesting) via an apheresis procedure; (2) freezing and storing the harvested cells until they are needed for transplantation; (3) providing a conditioning treatment, such as high-dose chemotherapy or radiation, to kill the remaining
      cancer cells the day before transplant; and (4) infusing the stored stem cells back to the patient intravenously via a catheter.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">To mobilize the patient&#8217;s stem cells from the bone marrow to the peripheral blood for harvesting, the current standard of care includes
      the administration of 5-8 daily doses of granulocyte colony stimulating factor (G-CSF), with or without 1-4 doses of plerixafor, and the performance of 1-4 apheresis sessions. For patients unable to mobilize sufficient numbers of cells for harvesting
      during this primary mobilization phase, rescue therapy is carried out, consisting of 1-4 additional doses of plerixafor on top of G-CSF, and the performance of an additional number of apheresis sessions as necessary. In light of this, an agent with
      superior mobilization activity may significantly reduce the mobilization and harvesting burden and associated risks of the ASCT process and lead to significant clinical and resource benefits.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About BioLineRx</div>
    <div style="text-align: justify; line-height: 1.25;">BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a late clinical-stage biopharmaceutical company focused on oncology. The Company&#8217;s business model
      is to in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development and/or commercialization.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s lead program, Motixafortide (BL-8040), is a cancer therapy platform that was successfully evaluated in a Phase 3 study in
      stem cell mobilization for autologous bone-marrow transplantation, has reported positive results from a pre-planned pharmacoeconomic study, has successfully completed a pre-NDA meeting with the FDA, and is currently in preparations for an NDA
      submission. Motixafortide was also successfully evaluated in a Phase 2a study for the treatment of pancreatic cancer in combination with KEYTRUDA<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and chemotherapy under a clinical trial collaboration agreement with MSD (BioLineRx owns all
      rights to Motixafortide), and is currently being studied in combination with LIBTAYO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and chemotherapy as a first-line PDAC therapy.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">BioLineRx is also developing a second oncology program, AGI-134, an immunotherapy treatment for multiple solid tumors that is currently
      being investigated in a Phase 1/2a study.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">For additional information on BioLineRx, please visit the Company&#8217;s website at <u>www.biolinerx.com</u>, where you can review the Company&#8217;s SEC filings, press releases, announcements and events.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Various statements in this release concerning BioLineRx's future expectations constitute "forward-looking
      statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These
      forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or
      implied by such forward-looking statements. Factors that could cause BioLineRx's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the initiation, timing, progress
      and results of BioLineRx's preclinical studies, clinical trials and other therapeutic candidate development efforts; BioLineRx's ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or
      clinical trials; BioLineRx's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of BioLineRx's therapeutic
      candidates; BioLineRx's ability to establish and maintain corporate collaborations; BioLineRx's ability to integrate new therapeutic candidates and new personnel; the interpretation of the properties and characteristics of BioLineRx's therapeutic
      candidates and of the results obtained with its therapeutic candidates in preclinical studies or clinical trials; the implementation of BioLineRx's business model and strategic plans for its business and therapeutic candidates; the scope of
      protection BioLineRx is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; estimates of
      BioLineRx's expenses, future revenues, capital requirements and its needs for additional financing; risks related to changes in healthcare laws, rules and regulations in the United States or elsewhere; competitive companies, technologies and
      BioLineRx's industry; risks related to the COVID-19 pandemic; and statements as to the impact of the political and security situation in Israel on BioLineRx's business. These and other factors are more fully discussed in the "Risk Factors" section of
      BioLineRx's most recent annual report on Form 20-F filed with the Securities and Exchange Commission on February 23, 2021. In addition, any forward-looking statements represent BioLineRx's views only as of the date of this release and should not be
      relied upon as representing its views as of any subsequent date. BioLineRx does not assume any obligation to update any forward-looking statements unless required by law.</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Contact:</div>
      <div style="text-align: justify; line-height: 1.25;">Tim McCarthy</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
      <div style="text-align: justify; line-height: 1.25;">+1-917-679-9282</div>
      <div style="text-align: justify; line-height: 1.25;"><u>tim@lifesciadvisors.com</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">or</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Moran Meir</div>
      <div style="text-align: justify; line-height: 1.25;">LifeSci Advisors, LLC</div>
      <div style="text-align: justify; line-height: 1.25;">+972-54-476-4945</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><u>moran@lifesciadvisors.com</u></div>
    <div style="text-align: justify; line-height: 1.25;"><u> <br>
      </u></div>
    <div style="text-align: justify; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u> </u></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 HP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *R/%&J3Z)X5U35+9(WGM+9YD60$J2
M!D9P0<?C6O7-_$'_ ))YX@_Z\9?_ $$U4=9(3V/'_P#A>WBC_GPTC_OS+_\
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M_';_ )$>S_[",?\ Z+DKY[KZ$^.W_(CV?_81C_\ 1<E?/=/!_P (,7\9[!\
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MC_%1],4445XAZH4444 %%%% !1110!XO\??]7HO^_)_(5XI7M?Q]_P!7HO\
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MY1^(?_)1=?\ ^OH_^@K7U=7RC\0_^2BZ_P#]?1_]!6G@?C?H&+_AF!9_\?\
M:_\ 7=/_ $(5]ER$K&S#J 37QI9_\?\ :_\ 7=/_ $(5]E3?ZF3_ '358[>)
M.#^%GQSJ;%M7OF/5KF4G_OLUN_#W^S/^$VL?[9^Q_8,/YGVS;Y73C.[BL#4?
M^0I>_P#7Q)_Z$:KUW./-"QQ\W+4N?3W_ !;#_J4/_):C_BV'_4H?^2U?,-%<
MWU3^\S?ZU_=1]/?\6P_ZE#_R6H_XMA_U*'_DM7S#11]4_O,/K7]U'T]_Q;#_
M *E#_P EJ4#X8D@ >$"2< ?Z-7S!3X/^/F'_ *Z+_,4/"?WF-8F[MRH^MO\
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M[:=8T\A"HP5SSDFHJ8:<(\TBX5X3=D<I\??]7HO^_)_(5XI7M?Q]_P!7HO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
